HIGHLIGHTS
- who: Jia Luo from the China Yokohama City University Medical have published the research work: Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis, in the Journal: (JOURNAL) of June/30,/2022
- how: In this study CR PR ORR and DCR were used to evaluate tumor treatment response. These results indicated that lenvatinib is associated with a longer PFS and higher response rates as compared to sorafenib revealing a significantly better therapeutic effect.
SUMMARY
Hepatocellular carcinoma (HCC), the most common type of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.